US 12,409,347

Application 18/762,296 · Granted Sep 9, 2025

Betacoronavirus mrna vaccines

Estimated expiration

October 21, 2036

9y 337d remaining

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
Earliest effective filing
Oct 21, 2016
+ 20 years
Oct 21, 2036
PTA +0d
Oct 21, 2036
TD applied
Oct 21, 2036
Final
Oct 21, 2036

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).

Calculation details

Base term

Filing date
July 2, 2024
Earliest effective filing
October 21, 2016
Issue date
September 9, 2025
PTA
0 days
Base expiry (before PTA)
October 21, 2036

October 21, 2016 + 20 years = October 21, 2036

  • Continuation of application 18/528,323, filed Dec 4, 2023, issued as US 12,403,335
  • Continuation of application 16/897,734, filed Jun 10, 2020, issued as US 11,872,278
  • Continuation of application 16/368,270, filed Mar 28, 2019, issued as US 10,702,599
  • Continuation of application 16/040,981, filed Jul 20, 2018, issued as US 10,272,150
  • Continuation of application 15/674,599, filed Aug 11, 2017, issued as US 10,064,934
  • Continuation of application PCTUS2016058327, filed Oct 21, 2016
  • Continuation of application PCTUS2016058327, filed Oct 21, 2016
  • Continuation of application 15/674,599, filed Aug 11, 2017, issued as US 10,064,934
  • Continuation of application PCTUS2016058327, filed Oct 21, 2016
  • Continuation of application 16/040,981, filed Jul 20, 2018, issued as US 10,272,150
  • Continuation of application 15/674,599, filed Aug 11, 2017, issued as US 10,064,934
  • Continuation of application PCTUS2016058327, filed Oct 21, 2016
  • Continuation of application 16/368,270, filed Mar 28, 2019, issued as US 10,702,599
  • Continuation of application 16/040,981, filed Jul 20, 2018, issued as US 10,272,150
  • Continuation of application 15/674,599, filed Aug 11, 2017, issued as US 10,064,934
  • Continuation of application PCTUS2016058327, filed Oct 21, 2016
  • Continuation of application 16/897,734, filed Jun 10, 2020, issued as US 11,872,278
  • Continuation of application 16/368,270, filed Mar 28, 2019, issued as US 10,702,599
  • Continuation of application 16/040,981, filed Jul 20, 2018, issued as US 10,272,150
  • Continuation of application 15/674,599, filed Aug 11, 2017, issued as US 10,064,934
  • Continuation of application PCTUS2016058327, filed Oct 21, 2016
  • PRO62/245,031 — Provisional — not used for base term
  • PRO62/244,813 — Provisional — not used for base term
  • PRO62/247,362 — Provisional — not used for base term
  • PRO62/244,946 — Provisional — not used for base term
  • PRO62/247,483 — Provisional — not used for base term
  • PRO62/247,394 — Provisional — not used for base term
  • PRO62/247,297 — Provisional — not used for base term
  • PRO62/244,802 — Provisional — not used for base term
  • PRO62/244,837 — Provisional — not used for base term
  • PRO62/247,362 — Provisional — not used for base term
  • PRO62/247,394 — Provisional — not used for base term
  • PRO62/247,483 — Provisional — not used for base term
  • PRO62/247,297 — Provisional — not used for base term
  • PRO62/244,802 — Provisional — not used for base term
  • PRO62/244,946 — Provisional — not used for base term
  • PRO62/244,813 — Provisional — not used for base term
  • PRO62/244,837 — Provisional — not used for base term
  • PRO62/245,031 — Provisional — not used for base term
  • PRO62/247,362 — Provisional — not used for base term
  • PRO62/247,394 — Provisional — not used for base term
  • PRO62/247,483 — Provisional — not used for base term
  • PRO62/247,297 — Provisional — not used for base term
  • PRO62/244,802 — Provisional — not used for base term
  • PRO62/244,946 — Provisional — not used for base term
  • PRO62/244,813 — Provisional — not used for base term
  • PRO62/244,837 — Provisional — not used for base term
  • PRO62/245,031 — Provisional — not used for base term
  • PRO62/247,362 — Provisional — not used for base term
  • PRO62/247,394 — Provisional — not used for base term
  • PRO62/247,483 — Provisional — not used for base term
  • PRO62/247,297 — Provisional — not used for base term
  • PRO62/244,802 — Provisional — not used for base term
  • PRO62/244,946 — Provisional — not used for base term
  • PRO62/244,813 — Provisional — not used for base term
  • PRO62/244,837 — Provisional — not used for base term
  • PRO62/245,031 — Provisional — not used for base term
  • PRO62/247,362 — Provisional — not used for base term
  • PRO62/247,394 — Provisional — not used for base term
  • PRO62/247,483 — Provisional — not used for base term
  • PRO62/247,297 — Provisional — not used for base term
  • PRO62/244,802 — Provisional — not used for base term
  • PRO62/244,946 — Provisional — not used for base term
  • PRO62/244,813 — Provisional — not used for base term
  • PRO62/244,837 — Provisional — not used for base term
  • PRO62/245,031 — Provisional — not used for base term
  • PRO62/247,362 — Provisional — not used for base term
  • PRO62/247,394 — Provisional — not used for base term
  • PRO62/247,483 — Provisional — not used for base term
  • PRO62/247,297 — Provisional — not used for base term
  • PRO62/244,802 — Provisional — not used for base term
  • PRO62/244,946 — Provisional — not used for base term
  • PRO62/244,813 — Provisional — not used for base term
  • PRO62/244,837 — Provisional — not used for base term
  • PRO62/245,031 — Provisional — not used for base term
  • PRO62/244,813 — Provisional — not used for base term
  • PRO62/245,031 — Provisional — not used for base term
  • PRO62/244,837 — Provisional — not used for base term
  • PRO62/244,946 — Provisional — not used for base term
  • PRO62/244,802 — Provisional — not used for base term
  • PRO62/247,483 — Provisional — not used for base term
  • PRO62/247,297 — Provisional — not used for base term
  • PRO62/247,362 — Provisional — not used for base term
  • PRO62/247,394 — Provisional — not used for base term

Terminal disclaimers

TD approved2 approved, 2 filed

TD caps expiration to October 21, 2036

  • US 12,409,347· Application 18/762,296(from application 18/762,296)Capping patent

    Betacoronavirus mrna vaccines

    Filing date
    Jul 2, 2024
    Earliest effective filing
    Oct 21, 2016
    Issue date
    Sep 9, 2025
    PTA
    0 days
    Calculated expiration
    Oct 21, 2036

    Continuation of 18/528,323, filed Dec 4, 2023, issued as US 12,403,335

    Continuation of 16/897,734, filed Jun 10, 2020, issued as US 11,872,278

    Continuation of 16/368,270, filed Mar 28, 2019, issued as US 10,702,599

    Continuation of 16/040,981, filed Jul 20, 2018, issued as US 10,272,150

    Continuation of 15/674,599, filed Aug 11, 2017, issued as US 10,064,934

    Continuation of PCTUS2016058327, filed Oct 21, 2016

    Continuation of PCTUS2016058327, filed Oct 21, 2016

    Continuation of 15/674,599, filed Aug 11, 2017, issued as US 10,064,934

    Continuation of PCTUS2016058327, filed Oct 21, 2016

    Continuation of 16/040,981, filed Jul 20, 2018, issued as US 10,272,150

    Continuation of 15/674,599, filed Aug 11, 2017, issued as US 10,064,934

    Continuation of PCTUS2016058327, filed Oct 21, 2016

    Continuation of 16/368,270, filed Mar 28, 2019, issued as US 10,702,599

    Continuation of 16/040,981, filed Jul 20, 2018, issued as US 10,272,150

    Continuation of 15/674,599, filed Aug 11, 2017, issued as US 10,064,934

    Continuation of PCTUS2016058327, filed Oct 21, 2016

    Continuation of 16/897,734, filed Jun 10, 2020, issued as US 11,872,278

    Continuation of 16/368,270, filed Mar 28, 2019, issued as US 10,702,599

    Continuation of 16/040,981, filed Jul 20, 2018, issued as US 10,272,150

    Continuation of 15/674,599, filed Aug 11, 2017, issued as US 10,064,934

    Continuation of PCTUS2016058327, filed Oct 21, 2016

    Oct 21, 2016 + 20y = Oct 21, 2036

  • US 12,551,734· Application 19/000,377(from application 19/000,377)

    Betacoronavirus mrna vaccines

    Filing date
    Dec 23, 2024
    Earliest effective filing
    Oct 21, 2016
    Issue date
    Feb 17, 2026
    PTA
    0 days
    Calculated expiration
    Oct 21, 2036

    Continuation of 18/762,372, filed Jul 2, 2024, issued as US 12,208,288

    Continuation of 18/528,323, filed Dec 4, 2023, issued as US 12,403,335

    Continuation of 16/897,734, filed Jun 10, 2020, issued as US 11,872,278

    Continuation of 16/368,270, filed Mar 28, 2019, issued as US 10,702,599

    Continuation of 16/040,981, filed Jul 20, 2018, issued as US 10,272,150

    Continuation of 15/674,599, filed Aug 11, 2017, issued as US 10,064,934

    Continuation of PCTUS2016058327, filed Oct 21, 2016

    Continuation of PCTUS2016058327, filed Oct 21, 2016

    Continuation of 15/674,599, filed Aug 11, 2017, issued as US 10,064,934

    Continuation of PCTUS2016058327, filed Oct 21, 2016

    Continuation of 16/040,981, filed Jul 20, 2018, issued as US 10,272,150

    Continuation of 15/674,599, filed Aug 11, 2017, issued as US 10,064,934

    Continuation of PCTUS2016058327, filed Oct 21, 2016

    Continuation of 16/368,270, filed Mar 28, 2019, issued as US 10,702,599

    Continuation of 16/040,981, filed Jul 20, 2018, issued as US 10,272,150

    Continuation of 15/674,599, filed Aug 11, 2017, issued as US 10,064,934

    Continuation of PCTUS2016058327, filed Oct 21, 2016

    Continuation of 16/897,734, filed Jun 10, 2020, issued as US 11,872,278

    Continuation of 16/368,270, filed Mar 28, 2019, issued as US 10,702,599

    Continuation of 16/040,981, filed Jul 20, 2018, issued as US 10,272,150

    Continuation of 15/674,599, filed Aug 11, 2017, issued as US 10,064,934

    Continuation of PCTUS2016058327, filed Oct 21, 2016

    Continuation of 18/528,323, filed Dec 4, 2023, issued as US 12,403,335

    Continuation of 18/762,296, filed Jul 2, 2024, issued as US 12,409,347

    Continuation of 18/528,323, filed Dec 4, 2023, issued as US 12,403,335

    Continuation of 16/897,734, filed Jun 10, 2020, issued as US 11,872,278

    Continuation of 16/368,270, filed Mar 28, 2019, issued as US 10,702,599

    Continuation of 16/040,981, filed Jul 20, 2018, issued as US 10,272,150

    Continuation of 15/674,599, filed Aug 11, 2017, issued as US 10,064,934

    Continuation of PCTUS2016058327, filed Oct 21, 2016

    Continuation of 18/762,384, filed Jul 2, 2024, issued as US 12,521,577

    Continuation of 18/528,323, filed Dec 4, 2023, issued as US 12,403,335

    Continuation of 16/897,734, filed Jun 10, 2020, issued as US 11,872,278

    Continuation of 16/368,270, filed Mar 28, 2019, issued as US 10,702,599

    Continuation of 16/040,981, filed Jul 20, 2018, issued as US 10,272,150

    Continuation of 15/674,599, filed Aug 11, 2017, issued as US 10,064,934

    Continuation of PCTUS2016058327, filed Oct 21, 2016

    Continuation of 16/897,734, filed Jun 10, 2020, issued as US 11,872,278

    Continuation of 16/368,270, filed Mar 28, 2019, issued as US 10,702,599

    Continuation of 16/040,981, filed Jul 20, 2018, issued as US 10,272,150

    Continuation of 15/674,599, filed Aug 11, 2017, issued as US 10,064,934

    Continuation of PCTUS2016058327, filed Oct 21, 2016

    Oct 21, 2016 + 20y = Oct 21, 2036

  • US 10,702,600· Application 16/805,587

    Betacoronavirus mrna vaccine

    Filing date
    Feb 28, 2020
    Earliest effective filing
    Oct 21, 2016
    Issue date
    Jul 7, 2020
    PTA
    0 days
    Calculated expiration
    Oct 21, 2036

    Continuation of 16/368,270, filed Mar 28, 2019, issued as US 10,702,599

    Continuation of 16/040,981, filed Jul 20, 2018, issued as US 10,272,150

    Continuation of 15/674,599, filed Aug 11, 2017, issued as US 10,064,934

    Continuation of PCTUS2016058327, filed Oct 21, 2016

    Continuation of PCTUS2016058327, filed Oct 21, 2016

    Continuation of 15/674,599, filed Aug 11, 2017, issued as US 10,064,934

    Continuation of PCTUS2016058327, filed Oct 21, 2016

    Continuation of 16/040,981, filed Jul 20, 2018, issued as US 10,272,150

    Continuation of 15/674,599, filed Aug 11, 2017, issued as US 10,064,934

    Continuation of PCTUS2016058327, filed Oct 21, 2016

    Oct 21, 2016 + 20y = Oct 21, 2036

  • US 10,933,127· Application 16/880,829

    Betacoronavirus mrna vaccine

    Filing date
    May 21, 2020
    Earliest effective filing
    Oct 21, 2016
    Issue date
    Mar 2, 2021
    PTA
    0 days
    Calculated expiration
    Oct 21, 2036

    Divisional of 16/805,587, filed Feb 28, 2020, issued as US 10,702,600

    Continuation of 16/368,270, filed Mar 28, 2019, issued as US 10,702,599

    Continuation of 16/040,981, filed Jul 20, 2018, issued as US 10,272,150

    Continuation of 15/674,599, filed Aug 11, 2017, issued as US 10,064,934

    Continuation of PCTUS2016058327, filed Oct 21, 2016

    Continuation of PCTUS2016058327, filed Oct 21, 2016

    Continuation of 15/674,599, filed Aug 11, 2017, issued as US 10,064,934

    Continuation of PCTUS2016058327, filed Oct 21, 2016

    Continuation of 16/040,981, filed Jul 20, 2018, issued as US 10,272,150

    Continuation of 15/674,599, filed Aug 11, 2017, issued as US 10,064,934

    Continuation of PCTUS2016058327, filed Oct 21, 2016

    Continuation of 16/368,270, filed Mar 28, 2019, issued as US 10,702,599

    Continuation of 16/040,981, filed Jul 20, 2018, issued as US 10,272,150

    Continuation of 15/674,599, filed Aug 11, 2017, issued as US 10,064,934

    Continuation of PCTUS2016058327, filed Oct 21, 2016

    Oct 21, 2016 + 20y = Oct 21, 2036

  • US 12,403,335· Application 18/528,323(from application 18/528,323)

    Betacoronavirus mrna vaccines

    Filing date
    Dec 4, 2023
    Earliest effective filing
    Oct 21, 2016
    Issue date
    Sep 2, 2025
    PTA
    0 days
    Calculated expiration
    Oct 21, 2036

    Continuation of 16/897,734, filed Jun 10, 2020, issued as US 11,872,278

    Continuation of 16/368,270, filed Mar 28, 2019, issued as US 10,702,599

    Continuation of 16/040,981, filed Jul 20, 2018, issued as US 10,272,150

    Continuation of 15/674,599, filed Aug 11, 2017, issued as US 10,064,934

    Continuation of PCTUS2016058327, filed Oct 21, 2016

    Continuation of PCTUS2016058327, filed Oct 21, 2016

    Continuation of 15/674,599, filed Aug 11, 2017, issued as US 10,064,934

    Continuation of PCTUS2016058327, filed Oct 21, 2016

    Continuation of 16/040,981, filed Jul 20, 2018, issued as US 10,272,150

    Continuation of 15/674,599, filed Aug 11, 2017, issued as US 10,064,934

    Continuation of PCTUS2016058327, filed Oct 21, 2016

    Continuation of 16/368,270, filed Mar 28, 2019, issued as US 10,702,599

    Continuation of 16/040,981, filed Jul 20, 2018, issued as US 10,272,150

    Continuation of 15/674,599, filed Aug 11, 2017, issued as US 10,064,934

    Continuation of PCTUS2016058327, filed Oct 21, 2016

    Oct 21, 2016 + 20y = Oct 21, 2036

Notes (1)

  • [TD_REFS_TRUNCATED] Found 7 TD references; resolving first 5 only

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 18/762,296 · US 12,409,347

PatentReply compiles the prosecution history behind US 12,409,347: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US12409347

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.